J Korean Soc Endocrinol.  2005 Aug;20(4):319-322. 10.3803/jkes.2005.20.4.319.

Sequential and Combination Therapy using Parathyroid Hormone for Osteoporosis

• Baek KH

• KMID: 2100462
• DOI: http://doi.org/10.3803/jkes.2005.20.4.319

Abstract

No Abstract available.

MeSH Terms

Osteoporosis*
Parathyroid Hormone*
Parathyroid Hormone

Reference

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001. 344:1434–1441.

2. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003. 18:9–17.

3. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998. 102:1627–1633.

4. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002. 87:4528–4535.

5. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R. Safety and efficacy of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003. 88:5212–5220.

6. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001. 16:157–165.

7. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003. 18:539–543.

8. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. Endocrine Reviews. 2005. 26:688–703.

9. Tashjian AH, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res. 2002. 17:1151–1161.

10. Gunness-Hey M, Hock JM. Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone. 1989. 10(6):447–452.

11. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos In. 2004. 15(12):992–997.

12. Black DM, Greenspan SL, Ensrud KE, Palermo L, Mc-Gowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003. 349:1207–1215.

13. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003. 349:1216–1226.

14. Heaney RP, Recker RR. Combination and sequential therapy for osteoporosis. N Engl J Med. 2005. 353:624–625.

15. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001. 16:925–931.

16. Ettinger B, San Martin JA, Crans GG, Pavo I. Differential effects of teriparatide after treatment with ralozifene or alendronate. J Bone Miner Res. 2004. 19:745–751.

17. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res. 1998. 13:1051–1055.

18. Roe EB, Sanchez SD, Cann CE, del Puerto GA, Pierini E, Arnaud CD. PTH-induced increases in bone density are preserved with estrogen: results from a follow-up year in postmenopausal osteoporosis. J Bone Miner Res. 2000. 15:Suppl 1. S193.

19. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000. 85:2129–2134.

20. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. 2004. 15:992–997.

21. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005. 353:555–565.

22. Sato M, Zeng GQ, Rowley E, Turner CH. LY353381 HCl: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34). Endocrinology. 1998. 139:4642–4651.

23. Iwaniec UT, Samnegard E, Cullen DM, Kimmel DB. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH. Bone. 2001. 29:352–360.

24. Rhee Y, Won YY, Baek MH, Lim SK. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats. J Bone Miner Res. 2004. 19:931–937.

25. Lane N, Morris S. New perspectives on parathyroid hormone therapy. Curr Opin Rheumatol. 2005. 17:467–474.